Peppermint oil reduces blood pressure by 8.48 mmHg in small study

Original Article ↗ Hacker News Discussion ↗

A small randomized trial reports that ingesting peppermint oil lowered systolic blood pressure by about 8.5 mmHg, prompting interest in whether a common herb could have meaningful cardiovascular effects. Commenters highlight major limitations: a tiny sample size, a questionable placebo that likely contained peppermint flavoring and sugar, and results far larger than those seen in prior mint studies, suggesting the effect may be overstated or confounded. The exchange broadens into herbal pharmacology, traditional uses of peppermint for digestion and IBS, and skepticism about how such preliminary findings will be amplified for supplements marketing.

Study design and limitations

  • Trial was very small (n≈40; peppermint group n=20 with 2 lost to follow-up) and short (20 days). Several commenters see it as exploratory at best.
  • Some argue this is publish-or-perish material and that tiny RCTs are common when fundable upside is low (unpatentable herb).
  • A systematic review/meta-analysis on mint is cited: pooled systolic BP effect is about −1.2 mmHg, whereas this trial reports ~−8.5 mmHg, making it a likely outlier that future reviews may down-weight or exclude.
  • Concerns about p‑hacking / “p<0.05 lottery” are raised, with suggestions that crossover designs or replication would be needed.

Placebo and peppermint cordial issue

  • Strong criticism that the “placebo” was a commercial peppermint cordial whose ingredients list includes generic “flavourings.”
  • Multiple commenters consider it very likely this cordial actually contains peppermint oil. If so, both groups consumed peppermint, undermining the comparison.
  • Others note the main difference may simply be extra water vs. sugary cordial, so the result could reflect reduced sugar intake rather than peppermint itself.

Mechanisms and pharmacology discussed

  • Proposed mechanisms include menthol acting as a calcium-channel blocker and TRPM8 agonist, leading to vasodilation and lower BP.
  • Other compounds (e.g., EGCG/epicatechin gallate in peppermint) are suggested as more plausible drivers of BP reduction via endothelial nitric oxide pathways.
  • There is detailed discussion of CYP enzyme inhibition, estrogen metabolism, TRPV1, opioid and GABAᴀ receptor modulation, and aromatherapy via nasal GPCRs.
  • Hormone-modulating and anti-androgen effects of related mints (e.g., spearmint) and pennyroyal’s historical reproductive effects are noted; overall effects remain unclear.

Other observed effects and anecdotes

  • Peppermint (oil, tea, or capsules) is widely reported in the thread to help with IBS, bloating, gas, mild laxative effects, digestion, seasickness, headaches, nausea, and relaxation/sedation for some.
  • Waist circumference changes in the trial are debated; some attribute minor reductions to debloating rather than fat loss.
  • Questions arise about differences between peppermint species (Mentha piperita vs. arvensis vs. spearmint) and between supplements vs. tea.

Meta-discussion

  • Mixed reactions: some enthusiasm for low-risk self-experimentation; substantial skepticism about overinterpreting a single small RCT and the likelihood of media and supplement-marketing hype.